Company Encyclopedia
View More
name
HULUWA
605199.SH
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceutical Group Co., Ltd.
3.144 T
605199.SHMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking207/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-18.24%E
    • Profit Margin-15.81%D
    • Gross Margin37.53%B
  • Growth ScoreE
    • Revenue YoY-31.37%E
    • Net Profit YoY8.73%C
    • Total Assets YoY-9.93%E
    • Net Assets YoY-38.52%E
  • Cash ScoreE
    • Cash Flow Margin-632.68%E
    • OCF YoY-31.37%E
  • Operating ScoreC
    • Turnover0.36C
  • Debt ScoreD
    • Gearing Ratio73.72%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ST HULUWA: Plans to sign a technology cooperation and development contract with related parties

    On October 17th, ST HULUWA announced that the company plans to sign two "Technology Cooperation Development Contracts" with its related party Hangzhou Kanglixian Pharmaceutical Technology Co., Ltd. to jointly develop the projects of "Ondansetron Oral Film" and "Idarucizumab Injection Concentrate Solution," with estimated contract amounts of 9.1 million yuan and 2.15 million yuan, totaling 11.25 million yuan

    Zhitong·
    SH
    605199
    +1.35%
    Zhitong·
    SH
    605199
    +1.35%

    ST HULUWA: Pediatric Lung Heat Cough and Wheezing Granules Approved for Clinical Trials

    According to the Zhitong Finance APP, ST HULUWA announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, which approves the clinical trial of the pediatric lung heat cough and asthma granules (for use in children with influenza)

    Zhitong·
    SH
    605199
    +1.35%
    Zhitong·
    SH
    605199
    +1.35%

    ST HULUWA has obtained the drug registration certificate for Cefdinir Capsules

    ST HULUWA recently obtained the drug registration certificate for Cefdinir capsules approved by the National Medical Products Administration. Cefdinir is a third-generation broad-spectrum cephalosporin, suitable for infections caused by various bacteria, including pharyngitis, pneumonia, and otitis media. The approval of this drug meets the technical requirements for the consistency evaluation of quality and efficacy of generic drugs

    Zhitong·
    SH
    605199
    +1.35%
    Zhitong·
    SH
    605199
    +1.35%

    ST HULUWA: Obtained Drug Registration Certificate

    ST HULUWA announced that the company recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for Metformin and Ertugliflozin Tablets and Inhalation Compound Ipratropium Bromide Solution. Among them, the research and development expenses for Metformin and Ertugliflozin Tablets have totaled 11.6007 million yuan, and the research and development expenses for Inhalation Compound Ipratropium Bromide Solution have totaled 3.1696 million yuan

    Zhitong·
    SH
    605199
    +1.35%
    Zhitong·
    SH
    605199
    +1.35%

    ST HULUWA: Net profit in the first half of 2025 decreased by 94.14% year-on-year

    ST HULUWA announced that its operating revenue in the first half of 2025 was 508 million yuan, a year-on-year decrease of 42.89%. The net profit was 2.4098 million yuan, a year-on-year decrease of 94.14%

    Zhitong·
    SH
    605199
    +1.35%
    Zhitong·
    SH
    605199
    +1.35%
    © 2025 Longbridge｜Disclaimer